NCT03984097View on ClinicalTrials.gov

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

TAK-079

TAK-079 subcutaneously.

DRUG

Lenalidomide

Lenalidomide orally.

DRUG

Dexamethasone

Dexamethasone orally.

DRUG

Bortezomib

Bortezomib subcutaneously.

DRUG

Pomalidomide

Pomalidomide orally.

Trial Locations (9)

10032

Columbia University Medical Center, New York

20817

American Oncology Partners of Maryland, PA, Bethesda

28204

Levine Cancer Institute, Charlotte

35211

Alabama Oncology, Birmingham

45220

Good Samaritan Hospital, Cincinnati

53226

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

77030

MD Anderson Cancer Center, Houston

93940

Pacific Cancer Care, Monterey

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY